Cellegy Pharmaceuticals (CLGY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cellegy Pharmaceuticals (CLGY)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Daryl Gresham who wrote ()	3/21/2000 10:20:00 AM
From: Magic212	Read Replies (1) of 322

RESEARCH ALERT - Cellegy started with a buy CHICAGO, March 20 (Reuters) - Craig Hallum Capital Group Inc. analyst Richard Leza on Monday started coverage of biopharmaceutical company Cellegy Pharmaceuticals Inc. (NASDAQ: CLGY) with a buy rating. The analyst said his 12- to 18-month price target for the company's stock is $16 a share. Shares of South San Francisco, Calif.-based Cellegy ended 3/16 lower at 7-9/16 on the Nasdaq market.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next